- Home
- KALV vs UFCS Comparison
KALV vs UFCS Comparison
Compare KALV & UFCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- UFCS
- Stock Information
- Founded
- KALV N/A
- UFCS 1946
- Country
- KALV United States
- UFCS United States
- Employees
- KALV N/A
- UFCS N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- UFCS Property-Casualty Insurers
- Sector
- KALV Health Care
- UFCS Finance
- Exchange
- KALV Nasdaq
- UFCS Nasdaq
- Market Cap
- KALV 796.4M
- UFCS 765.5M
- IPO Year
- KALV N/A
- UFCS N/A
- Fundamental
- Price
- KALV $11.10
- UFCS $30.89
- Analyst Decision
- KALV Strong Buy
- UFCS Buy
- Analyst Count
- KALV 8
- UFCS 2
- Target Price
- KALV $26.43
- UFCS $30.50
- AVG Volume (30 Days)
- KALV 1.5M
- UFCS 102.6K
- Earning Date
- KALV 12-04-2025
- UFCS 11-04-2025
- Dividend Yield
- KALV N/A
- UFCS 2.10%
- EPS Growth
- KALV N/A
- UFCS 143.32
- EPS
- KALV N/A
- UFCS 3.51
- Revenue
- KALV $1,426,000.00
- UFCS $1,322,727,000.00
- Revenue This Year
- KALV N/A
- UFCS $12.34
- Revenue Next Year
- KALV $209.38
- UFCS $14.56
- P/E Ratio
- KALV N/A
- UFCS $8.71
- Revenue Growth
- KALV N/A
- UFCS 14.18
- 52 Week Low
- KALV $7.30
- UFCS $19.33
- 52 Week High
- KALV $17.28
- UFCS $32.58
- Technical
- Relative Strength Index (RSI)
- KALV 38.98
- UFCS 51.85
- Support Level
- KALV $10.75
- UFCS $30.12
- Resistance Level
- KALV $12.23
- UFCS $31.47
- Average True Range (ATR)
- KALV 0.62
- UFCS 0.64
- MACD
- KALV -0.01
- UFCS -0.04
- Stochastic Oscillator
- KALV 23.41
- UFCS 60.18
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.